Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome
Pediatric Nephrology Jan 25, 2020
Parmentier C, et al. - Given the efficiency of rituximab (RTX) in steroid-dependent nephrotic syndrome (SDNS) in pediatric and adult patients, researchers undertook this inquiry to define hypogammaglobulinemia as a side effect of RTX therapy. They analyzed 107 pediatric patients (< 18 years old), recruited from four French pediatric nephrology centers, who were treated with RTX for SDNS between 2010 and 2015. Hypogammaglobulinemia was present in 21 patients prior to the start of RTX. Younger age at RTX start, with a median age of 8.2 years, was noted in patients who developed hypogammaglobulinemia. Findings revealed a frequent occurrence of hypogammaglobulinemia as a complication of RTX therapy in younger children managed for SDNS. Careful assessment of the use of RTX in children as well as adapting their clinical and biological follow-up to the age-dependent risk profile for hypogammaglobulinemia were recommended based on the findings.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries